Treatment of Selinexor in Combination With Clarithromycin, Pomalidomide and Dexamethasone for Relapsed Refractory Multiple Myeloma Patients
- Status
- TERMINATED
- Phase
- PHASE2
Clinical Trials Related to Selinexor
Related studies linked through entity extraction aliases.
A Study of Different Dosing Schedules of Selinexor in Sarcoma Patients
- Status
- COMPLETED
- Phase
- PHASE1
Study of Selinexor Plus DRd for Newly Diagnosed Multiple Myeloma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Safety and Efficacy of Selinexor in Combination With Pembrolizumab in Recurrent Advanced Melanoma
- Status
- TERMINATED
- Phase
- PHASE2
Selinexor, Pomalidomide, and Dexamethasone With or Without Carfilzomib for the Treatment of Patients With Relapsed Refractory Multiple Myeloma, The SCOPE Trial
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Selinexor, Daratumumab, Carfilzomib and Dexamethasone for the Treatment of High-Risk, Recurrent or Refractory Multiple Myeloma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Low-Dose Selinexor and Choline Salicylate for Non-Hodgkin or Hodgkin Lymphoma, Histiocytic/Dendritic Cell Neoplasm, or Relapsed or Refractory Multiple Myeloma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL)
- Status
- WITHDRAWN
- Phase
- PHASE1/PHASE2
Selinexor Plus Gemcitabine in Selected Advanced Soft-tissue Sarcoma and Osteosarcoma
- Status
- RECRUITING
- Phase
- PHASE1
A Study to Evaluate Single Agent Selinexor Versus Physician's Choice in Participants With Previously Treated Myelofibrosis
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Study of Selinexor in Combination With Ruxolitinib in Myelofibrosis
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
COVID-19 Prevention and Treatment in Cancer; a Sequential Multiple Assignment Randomised Trial;
- Status
- COMPLETED
- Phase
- PHASE3
Selinexor Treatment for Multiple Myeloma Patients Who Are Refractory to Lenalidomide-containing Therapy.
- Status
- RECRUITING
- Phase
- PHASE1
A Study of Selinexor in Combination With Standard of Care Therapy for Newly Diagnosed or Recurrent Glioblastoma
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
A Study of Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM), Seli and Bortezomib + LDD in Triple-class Refractory MM.
- Status
- RECRUITING
- Phase
- PHASE2
Evaluation of Activity and Safety of Two Regimens of Low Dose Oral Selinexor in Participants With Moderate or Severe COVID-19
- Status
- WITHDRAWN
- Phase
- PHASE2
Evaluation of Activity and Safety of Oral Selinexor in Participants With Severe COVID-19 Infection
- Status
- COMPLETED
- Phase
- PHASE2
Selinexor (KPT-330) in Combination With Temozolomide and Radiation Therapy in Patients With Newly Diagnosed Glioblastoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Selinexor as Single Agent and With Imatinib in Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (SeliGIST)
- Status
- UNKNOWN
- Phase
- PHASE1/PHASE2
Venetoclax and Selinexor in Treating Patients with Relapsed or Refractory High Risk Hematologic Malignancies
- Status
- COMPLETED
- Phase
- PHASE1